Scribe Therapeutics develops a platform for CRISPR-based genetic medicine. The company focuses on molecular engineering and integrated technologies for therapeutic use in genetic medicine.

Scribe Therapeutics

Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.

Prevail Therapeutics

Andreessen Horowitz

Avoro Capital Advisors

Avoro Ventures

Wellington Management

T. Rowe Price

Menlo Ventures

RA Capital Management

OrbiMed

Perceptive Advisors

Another summer, another annual beach day enjoyed with our Scribe family and friends! 

#NationalBeachDay #BayAreaBiotech

We will be at this week's Cold Spring Harbor Laboratory Genome Engineering: #CRISPR Frontiers meeting to share:

🧬 Our #CRISPRbyDesign approach
🧬 Advances in our epigenome editing platform and more

Looking forward to seeing you there to discuss how Scribe is engineering the future of epigenome editing!

#cshlcrispr24 #GeneEditing #EpigeneticEditing #GeneticMedicine #MolecularEngineering

Congratulations to our partners at Eli Lilly and Company on this new hub dedicated to accelerating genetic medicines!

What does the future of #healthcare look like? 

Our CEO Benjamin Oakes envisions one-and-done therapies that could treat conditions like cardiometabolic disease. In his TEDx Berkeley talk, he explains that engineering #CRISPR technology is key to developing effective genetic medicines for a broad range of diseases and helping underserved patients rewrite their genetic destinies.

Watch his full talk on the TEDx YouTube channel: https://lnkd.in/ghPuX9sq

TED Conferences University of California, Berkeley #GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

In BioSpace, Greg Slabodkin highlights our "data-driven engineering approach—CRISPR by Design—that enables Scribe to build systems that allow for different genome editing outcomes than what’s possible with Cas9." 

Read more about our genome and epigenome editing tools for developing in vivo #CRISPR-based genetic medicines for broad patient populations ➡️ https://ow.ly/HROE50T1n6R 

#GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

Next-generation #CRISPR technologies. In vivo therapies for sickle cell and cardiovascular disease. The future of genetic medicine, from gene editing to epigenetic editing.

At #AspenIdeasHealth, our CEO Benjamin Oakes, Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna, and CRISPR Therapeutics CEO Samarth Kulkarni discussed these topics and more.

Missed their Aspen Ideas discussion? Check out the video recording, now available on demand: https://lnkd.in/grDZ7wU7 

The Aspen Institute #CRISPRbyDesign #GeneEditing #MolecularEngineering #EpigeneticEditing #GeneticMedicine

SCRI

COM:SCRIBETX

Scribe Therapeutics